| Today’s Big NewsFeb 24, 2025 |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today! 
|
|
| By Gabrielle Masson Regeneron’s investigational gene therapy has been tied to notable hearing improvements in 10 of 11 children who were treated for a rare genetic condition that causes hearing loss. |
|
|
|
By Kevin Dunleavy Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. Of the world’s 22 biopharma companies that have reported quarterly revenues of at least $2 billion, only one posted a year-over-year decline. And that decline came with a caveat. |
By Conor Hale After hundreds of FDA employees were suddenly laid off last weekend, including dozens at the agency’s device center, the government has begun rescinding some of those cuts and attempting to rehire lost workers. |
By Gabrielle Masson After leaving the FDA, where she served as director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., is returning to her previous employer: Big Pharma Pfizer. |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT Softgels have emerged as a versatile dosage form, yet they are often overlooked. This webinar will explore the role of softgels in both early-stage and post-approval lifecycle management strategies. Learn about key considerations for launching with softgels, opportunities for post-approval switches to or from softgels, and how softgels compare to other dose forms. Register now. 
|
|
By Zoey Becker HHS secretary Robert F. Kennedy Jr. has been on the receiving end of two heated letters from lawmakers outlining the threats to innovation posed by mass firings at U.S. health agencies. |
By Conor Hale The company said its U.S. rollout represents the largest-ever commercial launch of a brain-computer interface technology, with Medtronic’s BrainSense platform reading changes in a patient’s neural activity in real-time and then adjusting therapy to suit. |
By Darren Incorvaia Celia Witten, M.D., Ph.D., is no longer deputy director of the FDA’s Center for Biologics Evaluation and Research, joining a long list of health agency leaders who have departed since President Donald Trump began his second term in office. |
By Fraiser Kansteiner Looking to avoid a repeat of the shortages that plagued Mounjaro and Zepbound during their initial rollouts, Eli Lilly is building supply of its oral GLP-1 contender orforglipron well before the drug’s expected approval in 2026. |
By Conor Hale The company said its approach has helped cut the number of discarded livers in half compared to simple cold storage. |
By Nick Paul Taylor Sanofi has shared a deeper dive into its 469 million euro bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck & Co. and Roche’s rival candidates. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Zoey Becker,Kevin Dunleavy In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dive into several of the biggest failures in clinical-stage drug development last year and discuss what the biopharma industry can learn from these setbacks. |
|
|---|
|
|
|
Tuesday, March 4, 2025 | 2pm ET / 11am PT Learn expert strategies for overcoming the unique challenges of early phase clinical trials, from preparing investigational products to maintaining blinding and sourcing controlled substances. This webinar provides actionable insights to optimize pharmacy activities and ensure trial success. Register now. 
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| Submissions Open Early August |
|
|
| |
|
